Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

 is a board-certified dermatologist and fellowship-trained pediatric dermatologist specializing in allergic contact dermatitis and occupational dermatitis in adults and children at Massachusetts General Hospital in Boston. He is actively involved in the American Contact Dermatitis Society in which he serves on the Pediatric Contact Dermatitis Working Group and the Interactive Media Committee. He is also an active member of the Society of Pediatric Dermatology, Pediatric Dermatology Research Alliance, and the American Academy of Dermatology

Articles

At the 2025 Revolutionizing Atopic Dermatitis Conference, JiaDe “Jeff” Yu, MD, MS, discussed the multifactorial nature of chronic hand eczema, highlighting its distinction from atopic dermatitis.

Reviewing the Multifactorial Nature of Chronic Hand Eczema and Upcoming Delgocitinib

professor and chair, department of dermatology, Director Temple Itch Center, Temple University Health System

At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory therapies, and more.

Chronic Itch Pathophysiology and Therapeutic Advances

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Catch up on coverage from the final day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.



Day 2 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Christopher Bunick, MD, PhD, is an associate professor of dermatology and physician-scientist at the Yale School of Medicine in New Haven, Connecticut, and 

At RAD 2025, Christopher Bunick, MD, PhD, presented 6-month data from the CorEvitas AD Registry, highlighting clinically meaningful skin clearance, itch reduction, and more in bio-naïve and bio-experienced adults treated with upadacitinib. 

Late-Breaking Data: Real-World Registry Data Supports Upadacitinib Efficacy in Moderate to Severe AD, Regardless of Biologic History 

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

Conference

1rem

Conference Archive

European Academy of Dermatology and Venereology

Risankizumab performed better in treating psoriasis that appears on the nails, hands and feet, palms and scalp sores.

EADV report shows that risankizumab is a consistent performer in psoriasis

The European Academy of Dermatology and Venerology (EADV) 2018 meeting takes this week in Paris. Visit our EADV conference news site to follow the developments from Paris.

EADV starts this week in Paris